Chiral Piperazine and Piperidine Building Blocks: Medicinal-Chemistry Uses and Outlook
Explore Rlavie chiral piperazine and piperidine building blocks for library design, lead optimization and route development.
Piperazine and piperidine motifs are widely used in medicinal chemistry because they provide three-dimensional shape, tunable basicity and convenient attachment points. Rlavie’s chiral building blocks help research teams introduce these features while starting from a defined stereochemical form.
Applications in discovery and development
Customers use these products for analogue-library construction, scaffold hopping, solubility and potency optimization, and route feasibility studies. Access to paired enantiomers is especially valuable for comparing biological activity, confirming stereochemical preference and preparing reference materials.
Market prospects
Stereochemically diverse libraries provide a potential application for protected and functionalized chiral heterocycles. The most attractive products will be those that save synthetic steps, offer clear stereochemical assignment and can be adapted to customer-specific substitution patterns.
Rlavie capabilities
Rlavie provides catalog options across piperazine and piperidine chemistry and can discuss custom synthesis for related analogues. Buyers can request information on identity, purity, stereochemical specification, packaging and lead time for their intended research use.
The two specific products below are piperazin-2-ones: their lactam carbonyl distinguishes them from simple piperazines, so basicity and reactivity must be evaluated for each structure.
Products to evaluate for your project
(R)-1,3-Dimethyl-piperazin-2-one (CAS 1240300-33-7); (S)-1,3-Dimethyl-piperazin-2-one (CAS 1240300-34-8).
Related Rlavie products
- (R)-1,3-Dimethyl-piperazin-2-one — CAS 1240300-33-7
- (S)-1,3-Dimethyl-piperazin-2-one — CAS 1240300-34-8
Contact Rlavie for specifications and a quotation, or discuss custom synthesis.
Resources and references
Links and product identities reviewed on 16 September 2026. Application outlook is qualitative; availability, specifications and suitability are confirmed by project enquiry.